|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort)
Tangui Barré 1 , Hélène Fontaine 2 , Clémence Ramier 3 , Vincent Di Beo 4 , Stanislas Pol 5 , Patrizia Carrieri 6 , Fabienne Marcellin 7 , Carole Cagnot 8 , Céline Dorival 9 , Jessica Zucman-Rossi 10 , Fabien Zoulim 11 , Fabrice Carrat 12 , Camelia Protopopescu 13
Affiliations
Affiliations
1
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Address: 27 Bd Jean Moulin, 13385, Marseille, Cedex 5, France. Electronic address: [email protected].
2
Université de Paris, Département d'Hépatologie et Addictologie, Hôpital Cochin, APHP, Address: 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France. Electronic address: [email protected].
3
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Address: 27 Bd Jean Moulin, 13385, Marseille, Cedex 5, France. Electronic address: [email protected].
4
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Address: 27 Bd Jean Moulin, 13385, Marseille, Cedex 5, France. Electronic address: [email protected].
5
Université de Paris, Département d'Hépatologie et Addictologie, Hôpital Cochin, APHP, Address: 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France. Electronic address: [email protected].
6
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Address: 27 Bd Jean Moulin, 13385, Marseille, Cedex 5, France. Electronic address: [email protected].
7
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Address: 27 Bd Jean Moulin, 13385, Marseille, Cedex 5, France. Electronic address: [email protected].
8
ANRS MIE (France Recherche Nord & Sud Sida-HIV Hépatites | Maladies Infectieuses Emergentes), Unit for Basic and Clinical Research on Viral Hepatitis, Address: 101 rue de Tolbiac, 75013, Paris, France. Electronic address: [email protected].
9
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Address: 27 rue Chaligny, 75012, Paris, France. Electronic address: [email protected].
10
Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, USPC, Université Paris Descartes, Université Paris Diderot, Address: 15 Rue de l'École de Médecine, 75006, Paris, France; Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Address: 20 Rue Leblanc, 75015, Paris, France. Electronic address: [email protected].
11
INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Address: 28 Rue Laennec, 69008, Lyon, France; University of Lyon, Université Claude-Bernard (UCBL), Address: 43 Boulevard du 11 Novembre 1918, 69100, Villeurbanne, France; Hospices Civils de Lyon (HCL), Address: 3 Quai des Célestins, 69002, Lyon, France. Electronic address: [email protected].
12
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Address: 27 rue Chaligny, 75012, Paris, France. Electronic address: [email protected].
13
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Address: 27 Bd Jean Moulin, 13385, Marseille, Cedex 5, France. Electronic address: [email protected].
PMID: 35124468 DOI: 10.1016/j.clnu.2022.01.016
Abstract
Background and aims: Patients chronically infected with hepatitis B virus (HBV) are at high risk of liver fibrosis, cirrhosis and liver cancer, despite recent therapeutic advances. It is therefore crucial to find non-pharmaceutical options for liver fibrosis prevention in this population. Using cross-sectional data from the ANRS CO22 Hepather cohort, we aimed to identify socio-demographic and modifiable risk factors for significant fibrosis in chronic HBV patients.
Methods: Logistic regression or Firth's penalized maximum likelihood logistic regression (according to outcome prevalence) multivariable models were used to test for associations between explanatory variables and significant fibrosis, as assessed by three non-invasive markers: aspartate aminotransferase to platelet ratio index (APRI), FIB-4, and gamma glutamyltransferase to platelet ratio (GPR). Analyses were stratified by HBV treatment status.
Results: The study population comprised 2065 untreated and 1727 treated chronic HBV patients. Elevated coffee consumption was consistently associated with a lower risk of elevated fibrosis biomarkers in all three treated-participant models, suggesting a dose-response relationship (adjusted odds ratios for ≥3 cups/day versus 0 cups/day: 0.16, 0.35 and 0.62, p ≤ 0.002, according to APRI, FIB-4 and GPR, respectively). Other modifiable risk factors included tobacco and alcohol use.
Conclusion: Elevated coffee consumption was consistently associated with a lower risk of significant liver fibrosis, as assessed by three non-invasive markers in treated chronic HBV patients. This result can be immediately used in real-world situations, as increasing coffee consumption may be beneficial for patients at risk of advanced liver disease.
Keywords: Caffeine; Coffee; France; Hepatitis B; Liver fibrosis.
Copyright © 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. |
|
发表于 2022-2-8 18:57
